Armata Retained Earnings vs Net Receivables Analysis

ARMP Stock

USD 1.95 0.04 2.01%

Armata Pharmaceuticals financial indicator trend analysis is way more than just evaluating Armata Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Armata Pharmaceuticals is a good investment. Please check the relationship between Armata Pharmaceuticals Retained Earnings and its Net Receivables accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Armata Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.

Retained Earnings vs Net Receivables

Retained Earnings vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Armata Pharmaceuticals Retained Earnings account and Net Receivables. At this time, the significance of the direction appears to have weak relationship.

The correlation between Armata Pharmaceuticals' Retained Earnings and Net Receivables is 0.35. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Armata Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Armata Pharmaceuticals' Retained Earnings and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Armata Pharmaceuticals are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Retained Earnings i.e., Armata Pharmaceuticals' Retained Earnings and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.35

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Net Receivables

Most indicators from Armata Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Armata Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Armata Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.As of 02/18/2025, Enterprise Value is likely to grow to about 211.4 M, while Selling General Administrative is likely to drop slightly above 10 M.

Armata Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Net Debt	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Short Term Investments	Common Stock
Total Assets		0.93	0.06	0.91	-0.48	0.98	0.1	0.21	0.66	0.99	0.67	0.97	0.91	0.42	-0.13	0.94	0.98	0.71	0.68	0.3	0.9	0.24	0.84	-0.24	0.13	-0.24
Short Long Term Debt Total	0.93		0.32	0.83	-0.7	0.96	0.06	0.11	0.5	0.95	0.5	0.93	0.96	0.21	-0.12	0.97	0.95	0.48	0.5	0.17	0.99	0.54	0.87	-0.16	0.04	-0.16
Other Current Liab	0.06	0.32		-0.19	-0.71	0.11	-0.09	-0.18	-0.02	0.11	-0.02	0.08	0.39	-0.8	-0.01	0.32	0.1	-0.34	-0.61	0.06	0.34	0.78	0.14	-0.09	0.03	-0.09
Total Current Liabilities	0.91	0.83	-0.19		-0.31	0.89	0.1	0.2	0.53	0.9	0.54	0.91	0.74	0.63	-0.11	0.8	0.89	0.67	0.88	0.21	0.81	0.16	0.72	-0.23	0.13	-0.23
Total Stockholder Equity	-0.48	-0.7	-0.71	-0.31		-0.49	0.25	-0.21	-0.39	-0.49	-0.39	-0.42	-0.8	0.33	-0.13	-0.75	-0.48	-0.16	0.07	-0.15	-0.68	-0.89	-0.42	0.08	-0.01	0.08
Property Plant And Equipment Net	0.98	0.96	0.11	0.89	-0.49		0.17	0.09	0.54	0.98	0.55	0.99	0.9	0.4	-0.21	0.93	1.0	0.62	0.65	0.15	0.95	0.29	0.92	-0.15	0.04	-0.15
Retained Earnings	0.1	0.06	-0.09	0.1	0.25	0.17		-0.44	-0.2	0.11	-0.2	0.21	-0.04	0.38	-0.98	-0.02	0.17	0.06	0.11	-0.36	0.09	-0.22	0.35	0.68	-0.62	0.68
Accounts Payable	0.21	0.11	-0.18	0.2	-0.21	0.09	-0.44		0.3	0.2	0.3	0.05	0.23	0.06	0.43	0.23	0.09	0.25	0.27	0.72	0.09	-0.04	-0.08	-0.36	0.36	-0.36
Cash	0.66	0.5	-0.02	0.53	-0.39	0.54	-0.2	0.3		0.58	1.0	0.57	0.63	0.25	0.18	0.64	0.55	0.89	0.43	0.26	0.41	0.07	0.35	-0.36	0.35	-0.36
Non Current Assets Total	0.99	0.95	0.11	0.9	-0.49	0.98	0.11	0.2	0.58		0.59	0.97	0.91	0.37	-0.14	0.94	0.98	0.63	0.65	0.31	0.93	0.27	0.86	-0.25	0.13	-0.25
Cash And Short Term Investments	0.67	0.5	-0.02	0.54	-0.39	0.55	-0.2	0.3	1.0	0.59		0.57	0.64	0.25	0.18	0.64	0.55	0.89	0.43	0.26	0.41	0.07	0.35	-0.36	0.35	-0.36
Common Stock Shares Outstanding	0.97	0.93	0.08	0.91	-0.42	0.99	0.21	0.05	0.57	0.97	0.57		0.86	0.43	-0.23	0.89	0.98	0.65	0.68	0.17	0.91	0.23	0.88	-0.21	0.1	-0.21
Non Current Liabilities Total	0.91	0.96	0.39	0.74	-0.8	0.9	-0.04	0.23	0.63	0.91	0.64	0.86		0.1	-0.04	1.0	0.89	0.54	0.4	0.28	0.94	0.57	0.78	-0.2	0.08	-0.2
Other Current Assets	0.42	0.21	-0.8	0.63	0.33	0.4	0.38	0.06	0.25	0.37	0.25	0.43	0.1		-0.33	0.18	0.41	0.62	0.88	-0.16	0.2	-0.45	0.36	0.24	-0.23	0.24
Other Stockholder Equity	-0.13	-0.12	-0.01	-0.11	-0.13	-0.21	-0.98	0.43	0.18	-0.14	0.18	-0.23	-0.04	-0.33		-0.05	-0.2	-0.05	-0.08	0.33	-0.15	0.11	-0.39	-0.7	0.7	-0.7
Total Liab	0.94	0.97	0.32	0.8	-0.75	0.93	-0.02	0.23	0.64	0.94	0.64	0.89	1.0	0.18	-0.05		0.92	0.58	0.48	0.28	0.95	0.53	0.8	-0.21	0.09	-0.21
Property Plant And Equipment Gross	0.98	0.95	0.1	0.89	-0.48	1.0	0.17	0.09	0.55	0.98	0.55	0.98	0.89	0.41	-0.2	0.92		0.63	0.65	0.15	0.94	0.27	0.92	-0.15	0.05	-0.15
Total Current Assets	0.71	0.48	-0.34	0.67	-0.16	0.62	0.06	0.25	0.89	0.63	0.89	0.65	0.54	0.62	-0.05	0.58	0.63		0.69	0.11	0.42	-0.17	0.5	-0.15	0.18	-0.15
Short Term Debt	0.68	0.5	-0.61	0.88	0.07	0.65	0.11	0.27	0.43	0.65	0.43	0.68	0.4	0.88	-0.08	0.48	0.65	0.69		0.15	0.48	-0.23	0.48	-0.16	0.11	-0.16
Intangible Assets	0.3	0.17	0.06	0.21	-0.15	0.15	-0.36	0.72	0.26	0.31	0.26	0.17	0.28	-0.16	0.33	0.28	0.15	0.11	0.15		0.15	-0.03	-0.09	-0.65	0.5	-0.65
Net Debt	0.9	0.99	0.34	0.81	-0.68	0.95	0.09	0.09	0.41	0.93	0.41	0.91	0.94	0.2	-0.15	0.95	0.94	0.42	0.48	0.15		0.55	0.88	-0.13	0.01	-0.13
Non Currrent Assets Other	0.24	0.54	0.78	0.16	-0.89	0.29	-0.22	-0.04	0.07	0.27	0.07	0.23	0.57	-0.45	0.11	0.53	0.27	-0.17	-0.23	-0.03	0.55		0.25	-0.01	-0.06	-0.01
Net Receivables	0.84	0.87	0.14	0.72	-0.42	0.92	0.35	-0.08	0.35	0.86	0.35	0.88	0.78	0.36	-0.39	0.8	0.92	0.5	0.48	-0.09	0.88	0.25		0.11	-0.18	0.11
Common Stock Total Equity	-0.24	-0.16	-0.09	-0.23	0.08	-0.15	0.68	-0.36	-0.36	-0.25	-0.36	-0.21	-0.2	0.24	-0.7	-0.21	-0.15	-0.15	-0.16	-0.65	-0.13	-0.01	0.11		-0.9	1.0
Short Term Investments	0.13	0.04	0.03	0.13	-0.01	0.04	-0.62	0.36	0.35	0.13	0.35	0.1	0.08	-0.23	0.7	0.09	0.05	0.18	0.11	0.5	0.01	-0.06	-0.18	-0.9		-0.9
Common Stock	-0.24	-0.16	-0.09	-0.23	0.08	-0.15	0.68	-0.36	-0.36	-0.25	-0.36	-0.21	-0.2	0.24	-0.7	-0.21	-0.15	-0.15	-0.16	-0.65	-0.13	-0.01	0.11	1.0	-0.9

Click cells to compare fundamentals

Armata Pharmaceuticals Account Relationship Matchups

Armata Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	39.5M	69.8M	95.8M	98.4M	113.1M	118.8M
Short Long Term Debt Total	13.2M	38.0M	48.8M	120.4M	138.4M	145.3M
Other Current Liab	3.5M	658K	(10.8M)	5.4M	4.9M	5.1M
Total Current Liabilities	6.7M	4.8M	24.9M	16.5M	18.9M	19.9M
Total Stockholder Equity	18.9M	25.4M	36.1M	(32.1M)	(28.9M)	(27.4M)
Property Plant And Equipment Net	12.8M	38.1M	46.7M	57.3M	65.9M	69.2M
Retained Earnings	(179.7M)	(202.9M)	(239.8M)	(308.8M)	(277.9M)	(291.8M)
Accounts Payable	956K	1.1M	1.7M	1.6M	1.4M	1.3M
Cash	9.6M	10.3M	14.9M	13.5M	15.6M	11.2M
Non Current Assets Total	28.7M	54.8M	68.8M	79.2M	91.1M	95.6M
Cash And Short Term Investments	9.6M	10.3M	14.9M	13.5M	15.6M	11.3M
Common Stock Shares Outstanding	16.4M	24.1M	34.3M	36.1M	41.5M	43.6M
Liabilities And Stockholders Equity	39.5M	69.8M	95.8M	98.4M	113.1M	118.8M
Non Current Liabilities Total	14.0M	39.6M	34.9M	114.0M	131.1M	137.6M
Other Current Assets	636K	1.7M	15.9M	2.3M	2.0M	2.3M
Other Stockholder Equity	198.4M	228.0M	275.5M	276.4M	317.9M	251.6M
Total Liab	20.7M	44.4M	59.8M	130.4M	150.0M	157.5M
Property Plant And Equipment Gross	12.8M	48.3M	57.8M	69.1M	79.5M	83.4M
Total Current Assets	10.8M	15.0M	27.0M	19.2M	17.2M	11.1M
Short Term Debt	2.3M	3.0M	34.0M	9.5M	10.9M	11.4M
Net Debt	3.5M	27.7M	34.0M	106.8M	122.9M	129.0M
Non Currrent Assets Other	(2.1M)	(8.3M)	(9.6M)	8.2M	7.4M	7.7M
Common Stock Total Equity	99K	187K	271K	361K	324.9K	308.7K
Common Stock	99K	187K	271K	361K	324.9K	308.7K
Capital Surpluse	172.0M	198.4M	228.0M	275.5M	247.9M	245.6M
Property Plant Equipment	4.2M	12.8M	2.2M	3.6M	4.2M	4.4M
Net Tangible Assets	11.1M	15.4M	11.7M	22.3M	25.7M	17.0M
Other Assets	(1K)	23.1M	13.2M	18.6M	21.4M	22.5M
Net Invested Capital	19.6M	25.4M	36.1M	50.2M	57.8M	60.7M
Net Working Capital	4.1M	10.2M	2.2M	2.7M	2.4M	3.5M

Additional Tools for Armata Stock Analysis

When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Armata Retained Earnings vs Net Receivables Analysis

Retained Earnings vs Net Receivables

Retained Earnings vs Net Receivables Correlation Analysis

Correlation Coefficient

Retained Earnings

Net Receivables

Armata Pharmaceuticals fundamental ratios Correlations

Armata Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Armata Pharmaceuticals fundamental ratios Accounts

Additional Tools for Armata Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 1.0	Non Current Liabilities Total
Common Stock	+ 1.0	Common Stock Total Equity
Non Current Assets Total	+ 0.99	Total Assets
Net Debt	+ 0.99	Short Long Term Debt Total

Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock	- 0.9	Short Term Investments
Short Term Investments	- 0.9	Common Stock Total Equity
Non Currrent Assets Other	- 0.89	Total Stockholder Equity
Non Current Liabilities Total	- 0.8	Total Stockholder Equity
Other Current Assets	- 0.8	Other Current Liab